Flexion Therapeutics Offers Final FX006 Data from Closed Phase 2b Dose-Ranging Trial at JBJS
June 03, 2015 at 16:49 PM EDT
Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced that a manuscript describing final study results from a completed Phase 2b ...